[go: up one dir, main page]

BR9811569A - Compounds that inhibit vla-4-mediated leukocyte adhesion - Google Patents

Compounds that inhibit vla-4-mediated leukocyte adhesion

Info

Publication number
BR9811569A
BR9811569A BR9811569-3A BR9811569A BR9811569A BR 9811569 A BR9811569 A BR 9811569A BR 9811569 A BR9811569 A BR 9811569A BR 9811569 A BR9811569 A BR 9811569A
Authority
BR
Brazil
Prior art keywords
compounds
leukocyte adhesion
vla
inhibit
mediated leukocyte
Prior art date
Application number
BR9811569-3A
Other languages
Portuguese (pt)
Inventor
Michael S Dappen
Darren B Dressen
Francine S Grant
Michael A Pleiss
Cynthia Y Robinson
Dimitrios Sarantakis
Eugene D Thorsett
Original Assignee
Elan Pharm Inc
American Home Prod
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Pharm Inc, American Home Prod filed Critical Elan Pharm Inc
Publication of BR9811569A publication Critical patent/BR9811569A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/0606—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing heteroatoms not provided for by C07K5/06086 - C07K5/06139, e.g. Ser, Met, Cys, Thr
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06104—Dipeptides with the first amino acid being acidic
    • C07K5/06113—Asp- or Asn-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)

Abstract

Patente de Invenção: <B>"COMPOSTOS QUE INIBEM A ADESãO DE LEUCóCITO MEDIADA POR VLA-4"<D>. São descritos compostos que ligam VLA-4. Alguns desses compostos também inibem a adesão de leucócito e, em particular, a adesão de leucócito mediada por VLA-4. Tais compostos são úteis no tratamento de doenças inflamatórias em paciente mamífero, por exemplo, ser humano, tal como asma, doença de Alzheimer, aterosclerose, Demência da AIDS, diabetes, doença inflamatória do intestino, artrite reumatóide, transplante de tecido, metástase de tumor e isquemia do miocárdio. Os compostos podem ser também administrados para o tratamento de doenças inflamatórias cerebrais tal como esclerose múltipla.Invention Patent: <B> "COMPOUNDS THAT INHIBIT VLA-4 MEDIATED LEUKOCYTE ADHESION" <D>. Compounds that bind VLA-4 are described. Some of these compounds also inhibit leukocyte adhesion and, in particular, VLA-4 mediated leukocyte adhesion. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, for example, a human being, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compounds can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.

BR9811569-3A 1997-07-31 1998-07-31 Compounds that inhibit vla-4-mediated leukocyte adhesion BR9811569A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90441697A 1997-07-31 1997-07-31
PCT/US1998/015952 WO1999006433A1 (en) 1997-07-31 1998-07-31 Compounds which inhibit leukocyte adhesion mediated by vla-4

Publications (1)

Publication Number Publication Date
BR9811569A true BR9811569A (en) 2000-09-19

Family

ID=25419117

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9811569-3A BR9811569A (en) 1997-07-31 1998-07-31 Compounds that inhibit vla-4-mediated leukocyte adhesion

Country Status (12)

Country Link
EP (1) EP1001973A1 (en)
JP (1) JP2001512136A (en)
KR (1) KR20010022423A (en)
CN (1) CN1265669A (en)
AU (1) AU8678698A (en)
BR (1) BR9811569A (en)
CA (1) CA2290746A1 (en)
HU (1) HUP0004529A3 (en)
IL (1) IL133641A0 (en)
NO (1) NO20000451L (en)
PL (1) PL338506A1 (en)
WO (1) WO1999006433A1 (en)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6903075B1 (en) 1997-05-29 2005-06-07 Merck & Co., Inc. Heterocyclic amide compounds as cell adhesion inhibitors
EP0998282A4 (en) * 1997-05-29 2000-08-30 Merck & Co Inc SULFAMIDES FOR USE AS CELL ADHESION INHIBITORS
US6221888B1 (en) 1997-05-29 2001-04-24 Merck & Co., Inc. Sulfonamides as cell adhesion inhibitors
WO1998054207A1 (en) * 1997-05-30 1998-12-03 Celltech Therapeutics Limited Anti-inflammatory tyrosine derivatives
DE69818049T2 (en) 1997-06-23 2004-07-15 Tanabe Seiyaku Co., Ltd. INHIBITORS OF ALPHA4-BETA1 MEDIATED CELL ADHESION
MY153569A (en) 1998-01-20 2015-02-27 Mitsubishi Tanabe Pharma Corp Inhibitors of ?4 mediated cell adhesion
US6329372B1 (en) 1998-01-27 2001-12-11 Celltech Therapeutics Limited Phenylalanine derivatives
WO1999043642A1 (en) 1998-02-26 1999-09-02 Celltech Therapeutics Limited Phenylalanine derivatives as inhibitors of alpha4 integrins
US6521626B1 (en) 1998-03-24 2003-02-18 Celltech R&D Limited Thiocarboxamide derivatives
GB9811159D0 (en) 1998-05-22 1998-07-22 Celltech Therapeutics Ltd Chemical compounds
GB9811969D0 (en) 1998-06-03 1998-07-29 Celltech Therapeutics Ltd Chemical compounds
US6685617B1 (en) 1998-06-23 2004-02-03 Pharmacia & Upjohn Company Inhibitors of α4β1 mediated cell adhesion
GB9814414D0 (en) 1998-07-03 1998-09-02 Celltech Therapeutics Ltd Chemical compounds
GB9821061D0 (en) 1998-09-28 1998-11-18 Celltech Therapeutics Ltd Chemical compounds
GB9821222D0 (en) 1998-09-30 1998-11-25 Celltech Therapeutics Ltd Chemical compounds
GB9825652D0 (en) 1998-11-23 1999-01-13 Celltech Therapeutics Ltd Chemical compounds
GB9826174D0 (en) 1998-11-30 1999-01-20 Celltech Therapeutics Ltd Chemical compounds
US6545003B1 (en) 1999-01-22 2003-04-08 Elan Pharmaceuticals, Inc. Fused ring heteroaryl and heterocyclic compounds which inhibit leukocyte adhesion mediated by VLA-4
CZ20012361A3 (en) 1999-01-22 2001-12-12 Elan Pharmaceuticals, Inc. Method for treating disease mediated by VLA-4, compound and pharmaceutical preparation
US6436904B1 (en) 1999-01-25 2002-08-20 Elan Pharmaceuticals, Inc. Compounds which inhibit leukocyte adhesion mediated by VLA-4
US6518283B1 (en) 1999-05-28 2003-02-11 Celltech R&D Limited Squaric acid derivatives
PT1265606E (en) 1999-08-13 2007-01-31 Biogen Idec Inc Cell adhesion inhibitors
US6534513B1 (en) 1999-09-29 2003-03-18 Celltech R&D Limited Phenylalkanoic acid derivatives
US6455539B2 (en) 1999-12-23 2002-09-24 Celltech R&D Limited Squaric acid derivates
KR20020067050A (en) 1999-12-28 2002-08-21 화이자 프로덕츠 인코포레이티드 Non-peptidyl inhibitors of vla-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases
JP2003531141A (en) 2000-04-17 2003-10-21 セルテック アール アンド ディ リミテッド Enamine derivatives
US6545013B2 (en) 2000-05-30 2003-04-08 Celltech R&D Limited 2,7-naphthyridine derivatives
US6403608B1 (en) 2000-05-30 2002-06-11 Celltech R&D, Ltd. 3-Substituted isoquinolin-1-yl derivatives
US6960597B2 (en) 2000-06-30 2005-11-01 Orth-Mcneil Pharmaceutical, Inc. Aza-bridged-bicyclic amino acid derivatives as α4 integrin antagonists
WO2002004426A1 (en) 2000-07-07 2002-01-17 Celltech R & D Limited Squaric acid derivatives containing a bicyclic heteroaromatic ring as integrin antagonists
JP2004505110A (en) 2000-08-02 2004-02-19 セルテック　アール　アンド　ディ　リミテッド 3-position substituted isoquinolin-1-yl derivative
MY129000A (en) 2000-08-31 2007-03-30 Tanabe Seiyaku Co INHIBITORS OF a4 MEDIATED CELL ADHESION
WO2003024933A1 (en) * 2001-09-12 2003-03-27 Kaken Pharmaceutical Co., Ltd. 2-phenyl-3-heteroarylpropionic acid derivative or salt thereof and medicine containing the same
MY140707A (en) 2002-02-28 2010-01-15 Mitsubishi Tanabe Pharma Corp Process for preparing a phenylalanine derivative and intermediates thereof
TWI281470B (en) 2002-05-24 2007-05-21 Elan Pharm Inc Heterocyclic compounds which inhibit leukocyte adhesion mediated by alpha4 integrins
TW200307671A (en) 2002-05-24 2003-12-16 Elan Pharm Inc Heteroaryl compounds which inhibit leukocyte adhesion mediated by α 4 integrins
FR2869904B1 (en) * 2004-05-07 2006-07-28 Fournier S A Sa Lab MODULATORS OF LXR RECEIVERS
US7196112B2 (en) 2004-07-16 2007-03-27 Biogen Idec Ma Inc. Cell adhesion inhibitors
EP1996559A1 (en) 2006-02-27 2008-12-03 Elan Pharmaceuticals Inc. Pyrimidinyl sulfonamide compounds which inhibit leukocyte adhesion mediated by vla-4
AU2008219007A1 (en) 2007-02-20 2008-08-28 Merrimack Pharmaceuticals, Inc. Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist
JP5639039B2 (en) 2008-04-11 2014-12-10 メリマック ファーマシューティカルズ インコーポレーティッド Human serum albumin linker and its conjugates
US20100160322A1 (en) 2008-12-04 2010-06-24 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US8557983B2 (en) 2008-12-04 2013-10-15 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US8586754B2 (en) 2008-12-05 2013-11-19 Abbvie Inc. BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
US8563735B2 (en) 2008-12-05 2013-10-22 Abbvie Inc. Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2679903B1 (en) * 1991-08-02 1993-12-03 Elf Sanofi DERIVATIVES OF N-SULFONYL INDOLINE CARRYING AN AMIDIC FUNCTION, THEIR PREPARATION, THE PHARMACEUTICAL COMPOSITIONS CONTAINING SAME.
WO1994007815A2 (en) * 1992-09-25 1994-04-14 Abbott Laboratories Small peptide anaphylatoxin receptor ligands
JPH08504194A (en) * 1992-12-01 1996-05-07 メルク エンド カンパニー インコーポレーテッド Fibrinogen receptor antagonist
WO1995015973A1 (en) * 1993-12-06 1995-06-15 Cytel Corporation Cs-1 peptidomimetics, compositions and methods of using the same
JPH0873422A (en) * 1994-09-07 1996-03-19 Kdk Corp New amino acid ester and method for detecting leukocyte, esterase or protease
US6306840B1 (en) * 1995-01-23 2001-10-23 Biogen, Inc. Cell adhesion inhibitors

Also Published As

Publication number Publication date
NO20000451D0 (en) 2000-01-28
AU8678698A (en) 1999-02-22
CA2290746A1 (en) 1999-02-11
PL338506A1 (en) 2000-11-06
HUP0004529A2 (en) 2001-04-28
IL133641A0 (en) 2001-04-30
EP1001973A1 (en) 2000-05-24
HUP0004529A3 (en) 2001-05-28
NO20000451L (en) 2000-03-23
JP2001512136A (en) 2001-08-21
WO1999006433A1 (en) 1999-02-11
CN1265669A (en) 2000-09-06
KR20010022423A (en) 2001-03-15

Similar Documents

Publication Publication Date Title
BR9811569A (en) Compounds that inhibit vla-4-mediated leukocyte adhesion
BR9811598A (en) &#34;carbamyloxy compounds that inhibit vla-4-mediated leukocyte adhesion&#34;.
BR9811594A (en) Sulphonylated dipeptide compounds that inhibit vla-4 mediated leukocyte adhesion
BR9812118A (en) 4-Amino-phenylalanine-type compounds that inhibit vla-4-mediated leukocyte adhesion
BR9812114A (en) Substituted phenylalanine-type compounds that inhibit vla-4-mediated leukocyte adhesion
BR9811573A (en) Benzyl compounds that inhibit vla-4 mediated leukocyte adhesion
BR9812111A (en) Dipeptide and related compounds that inhibit vla-4-mediated leukocyte adhesion
BR9811599A (en) Dipetid compounds that inhibit vla-4 mediated leukocyte adhesion
BR0007663A (en) Acyl derivatives for use in the treatment of diseases related to vla-4
BRPI0513143A (en) multivalent vla-4 antagonists comprising polymeric moieties
ECSP045425A (en) HETEROCYCLIC COMPOUNDS THAT INHIBIT THE ADHESION OF LEUKOCYTES THROUGH INTEGRINS a4
EA200401561A1 (en) HETEROARRYLIC COMPOUNDS THAT INHIBIT MEDIATED ГР4-INTEGRINES leukocyte adhesion
WO2000043354A3 (en) Multicyclic compounds which inhibit leukocyte adhesion mediated by vla-4
AU3246600A (en) Alpha-aminoacetic acid derivatives useful as alpha 4 beta 7 receptor antagonists
WO2002008203A3 (en) 3-(heteroaryl) alanine derivatives-inhibitors of leukocyte adhesion mediated by vla-4
WO2002008201A3 (en) Beta-amino acid derivatives-inhibitors of leukocyte adhesion mediated by vla-4
WO2000043371A3 (en) Fused ring heteroaryl and heterocyclic compounds which inhibit leukocyte adhesion mediated by vla-4
WO2000043413A3 (en) Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by vla-4
DE602006020754D1 (en) CARBAMATE COMPOUNDS INHIBITING THE LEUKOCYTE ADHESION MEDIATED BY VLA-4
AR029611A1 (en) COMPOUNDS THAT INHIBIT THE ADHESION OF LEUCOCITS INTERMEDIATE BY VLA-4
AR026105A1 (en) HETEROARILO, HETEROCICLICO AND ILO COMPUTERS THAT

Legal Events

Date Code Title Description
FA10 Dismissal: dismissal - article 33 of industrial property law
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]